Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Inventory
Cash effect of the change in inventory; building inventory consumes cash.
Maze Therapeutics, Inc.NASDAQ: MAZE
Inventory · Q1 FY2026 · quarter ended Mar 2026
Inventory outflow grows to $0
Q1 FY2026 inventory was $0, compared with $0 a year earlier. Trailing-twelve-month inventory was $0.
Context
- Inventory increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly inventory holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Inventory history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Inventory vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so inventory is compared through growth and share of revenue rather than absolute size.
- Inventory amounts to 0.0% of revenue for MAZE, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $58.52M USD | +9478.1% | +100.7% | 5.8% | |
| LTM Mar 2026 | $22.15M USD | -18.0% | +4.0% | 5.2% | |
| LTM Sep 2026 | $4.88M USD | -237.2% | — | 0.7% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $0 USD | — | — | 0.0% |
| LTM Mar 2026 | $0 USD | — | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $0 USD | — | — | 0.0% |
| FY2025 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding MAZE) | — | -59.0% | +52.4% | 0.4% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.